Developer docs
API playgroundTry for free, no card

Search company profiles

Anaveon

Full company profile

uuid0002136

Namestring
Anaveon
Legal namestring
Anaveon AG
Websiteurl
anaveon.com
Company typeenum
Private
Founded yearint
2018
Descriptiontext

Anaveon AG is a Swiss clinical-stage biotechnology company headquartered at Tech Park Basel (Hochbergerstrasse 60C, CH-4057 Basel), founded in 2018 to develop engineered antibodies and cytokine-based fusion proteins that selectively eliminate or reprogram pathogenic immune cells. The company's therapeutic premise is that immune-mediated diseases arise from dysregulation of upstream regulatory nodes, and that targeting those nodes — rather than individual downstream mediators — can restore durable immune balance without broadly suppressing immune function.

The pipeline rests on a proprietary PD-1-targeted cytokine platform that uses non-blocking PD-1 epitopes to enable proximity-activated 'cis-signaling' delivery of cytokines to tumor-reactive or pathogenic T cells. The lead immunology asset, ANV200, is a precision-engineered PD-1-depleting antibody in preclinical development for autoimmune and inflammatory diseases, with clinical testing planned in the near future. The legacy oncology portfolio comprises ANV600 (sunekafusp alpha), a first-in-class PD-1-targeted IL-2R-βγ agonist currently in Phase 1 with clinical benefit data presented at ASCO 2026 (42% disease control as monotherapy, 59% with pembrolizumab, including a CR in a CPI-resistant NSCLC patient); ANV700, a preclinical PD-1-targeted IL-21 fusion protein; and ANV419, an earlier-generation IL-2 fusion from prior clinical work.

Anaveon is pre-revenue and operates an enterprise partnering model. The company is actively seeking global development and commercialization partners for its oncology portfolio (ANV600, ANV700) via license, co-development, or acquisition structures, while advancing its core immunology pipeline internally toward clinical development. To date, Anaveon has raised approximately CHF 110 million in a December 2021 Series B led by Forbion with participation from Syncona, Novartis Venture Fund, Cowen Healthcare Investments, Pfizer Ventures, and Pontifax. Investors also include Blue Owl. The company has 11–50 employees and in 2026 underwent a comprehensive leadership overhaul — appointing Thaminda Ramanayake (CEO), Eric Zanelli (CSO), Jill Jene (CBO), and Thomas P. Mathers (Chairman) — alongside a strategic pivot emphasizing immunology over pure oncology.

Short descriptiontext

Anaveon AG is a Swiss preclinical-stage biotechnology company developing engineered antibodies and cytokine-based fusion proteins that selectively eliminate or reprogram pathogenic immune cells for autoimmune and oncology indications. It seeks global pharmaceutical partners for its oncology portfolio while advancing lead immunology asset ANV200 toward the clinic.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersBasel, Switzerland
HQ citystring
Basel
HQ countrystring
Switzerland
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
engineered antibodies, cytokine therapeutics, immuno-oncology biologics, autoimmune disease therapies, precision biologics
Industry6 codes
PRIMARYHLAAABAF
Dendritic Cell & Other APC-based Therapies
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
SECONDARYHLAAAAAJ
Engineered Protein Therapeutics (de novo/AI-designed proteins, novel scaffolds)
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
SECONDARYHLAAAAAA
Monoclonal Antibody Therapeutics (mAbs)
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
SECONDARYHLAAAEAD
Vaccine Technology Platforms (mRNA, viral vector, protein subunit, inactivated/live-attenuated, VLP, DNA)
Healthcare & Life Sciences/Biotechnology & Biologics/Vaccines & Immunization Biologics
SECONDARYHLAAANAK
Personalized Therapeutic Design (neoantigen vaccines, individualized cell/gene therapies)
SECONDARYHLAAAEAH
Immunoglobulins & Passive Immunization Biologics (IVIG, hyperimmune globulins, antitoxins)
Healthcare & Life Sciences/Biotechnology & Biologics/Vaccines & Immunization Biologics
NAICS code1 code
  • Pharmaceutical Preparation Manufacturing325412
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Biopharmaceuticals
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Pipeline Development and Licensing
TypeLicensing Royalties
Description

Pre-revenue preclinical biotech company. Primary value creation through advancing proprietary immunology pipeline (ANV200, ANV600, ANV700) toward clinical milestones, with intent to partner or out-license oncology assets. Revenue model will depend on eventual clinical and commercial partnerships, licensing deals, or co-development arrangements.

anaveon.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Personnel, Technology or R&D, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Anaveon develops precision-engineered antibodies and cytokine-based fusion proteins that act on upstream regulatory nodes of the immune system to selectively eliminate or reprogram pathogenic immune cells. Its lead immunology asset, ANV200, is a precision-engineered antibody designed for deep depletion of PD-1-expressing pathogenic T cells in autoimmune diseases, while its legacy oncology portfolio (ANV600, ANV700, ANV419) is being advanced through clinical and preclinical development and is open to global pharmaceutical partnering, licensing, co-development, or acquisition.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 6 values shown
  • Disease control (CR, PR, or SD) observed in 42% of patients treated with ANV600 monotherapy and 59% of patients receiving ANV600 plus pembrolizumab
+5 more records
Product overview1 text field

Anaveon is developing a portfolio of engineered antibodies and cytokine-based therapies designed to selectively eliminate or reprogram pathogenic immune cells. The core pipeline includes ANV200 (preclinical, lead immunology asset for autoimmune diseases), while the legacy oncology portfolio includes ANV600 (Phase 1 IL-2R-βγ agonist), ANV700 (preclinical IL-21 fusion), and ANV419 (earlier generation IL-2 fusion). The company is seeking partners for its oncology assets while prioritizing its immunology pipeline.

Product and service3 records
1ANV200
CategoryPrecision-engineered antibody therapeutic
Description

ANV200 is a precision-engineered antibody designed for deep depletion of the full spectrum of PD-1-expressing pathogenic T cells that drive harmful immune responses in autoimmune diseases. It acts on a key upstream control point of the immune system to reset pathogenic immune responses and restore tissue homeostasis, and is intended to influence multiple downstream disease mechanisms. The asset is currently in preclinical development, with clinical testing planned in the near future. It is being advanced as Anaveon's lead immunology asset.

2ANV600 (sunekafusp alpha)
CategoryPD-1-targeted cytokine agonist therapeutic
Description

ANV600 (sunekafusp alpha) is a first-in-class, non-blocking PD-1-targeted IL-2R-βγ agonist designed to selectively expand tumor-reactive PD-1+ CD8+ effector T cells while reducing toxicities historically associated with IL-2 therapy. It binds PD-1 on a unique non-blocking epitope distinct from checkpoint inhibitors and aims to activate tumor antigen-experienced T cells within the tumor microenvironment, with potential in checkpoint-refractory tumors and in combination with checkpoint inhibitors. The asset is in Phase 1 clinical development (EXPAND-1) and is part of the legacy oncology portfolio Anaveon is actively seeking to partner.

3ANV419
CategoryIL-2/anti-IL-2 fusion protein therapeutic
Description

ANV419 is an earlier-generation IL-2/anti-IL-2 fusion protein (not PD-1-targeted) with demonstrated safety in prior clinical studies. It is positioned as part of Anaveon's legacy oncology portfolio alongside ANV600 and ANV700, and is included in the oncology assets the company is actively seeking to partner, license, co-develop, or divest.

Scale indicator3 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Thaminda Ramanayake, now CEO of Anaveon, played a key role in CureVac's transformation and its acquisition by BioNTech in 2025. This represents a historical personal connection rather than a direct company-to-company partnership.

Recent move5 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Clinical-stage immuno-oncology company developing engineered IL-2/IL-4 Superkines and PD-1-IL-2 fusion proteins (MDNA11) — directly comparable mechanism and indication overlap with Anaveon's ANV600 and proximity-activated cytokine strategy.

TypeDirect peer
Description

Clinical-stage biotech using its PREDATOR/INDUKINE platforms to engineer tumor-selective, conditionally activated cytokine therapeutics — directly parallel to Anaveon's PD-1-targeted cytokine engineering approach.

TypeDirect peer
Description

Developer of long-acting IL-7 (NT-I7/efineptakin alfa) and other cytokine-based immunotherapies — comparable cytokine engineering focus with overlapping oncology and immunology applications.

TypeDirect peer
Description

Clinical-stage biotech developing bicyclic peptide-based precision oncology therapeutics including immune cell engagers — comparable engineered biologic platform philosophy targeting tumor-selective immune activation.

TypeDirect peer
Description

Clinical-stage biotech using AI-driven antibody engineering to develop precision immuno-oncology biologics, including PD-1-targeting candidates — comparable precision biologic approach with similar tumor-selective antibody engineering philosophy.

TypeDirect peer
Description

Multi-asset clinical-stage oncology company developing precision immunotherapies with similar partnered-program development model and platform-extension mindset.

7Hookipa Pharma
TypeEmerging player
Description

Clinical-stage biotech developing arenavirus-based immunotherapies to induce potent T cell responses against oncology targets — overlapping immunotherapy focus with comparable precision immune-activation approach.

TypeEmerging player
Description

Clinical-stage computational immunology company developing antibody-based therapeutics for cancer immunotherapy — comparable precision biologics development with computational discovery angle.

TypeBroad incumbent
Description

Major pharmaceutical company with a leading immunology/autoimmune franchise (Taltz, Olumiant) and active acquirer in the space — relevant as a potential strategic acquirer/partner and as the incumbent benchmark in autoimmune precision biologics.

TypeBroad incumbent
Description

Major pharmaceutical company with significant autoimmune and immunology franchise (Dupixent) and a venture arm that has historically backed cytokine engineering platforms — relevant both as a potential acquirer and as an incumbent benchmark.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature6 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles4 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds2 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors6 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Anaveon

Biopharmaceuticalsanaveon.com

Anaveon AG is a Swiss preclinical-stage biotechnology company developing engineered antibodies and cytokine-based fusion proteins that selectively eliminate or reprogram pathogenic immune cells for autoimmune and oncology indications. It seeks global pharmaceutical partners for its oncology portfolio while advancing lead immunology asset ANV200 toward the clinic.

What Anaveon does

Anaveon AG is a Swiss clinical-stage biotechnology company headquartered at Tech Park Basel (Hochbergerstrasse 60C, CH-4057 Basel), founded in 2018 to develop engineered antibodies and cytokine-based fusion proteins that selectively eliminate or reprogram pathogenic immune cells. The company's therapeutic premise is that immune-mediated diseases arise from dysregulation of upstream regulatory nodes, and that targeting those nodes — rather than individual downstream mediators — can restore durable immune balance without broadly suppressing immune function.

The pipeline rests on a proprietary PD-1-targeted cytokine platform that uses non-blocking PD-1 epitopes to enable proximity-activated 'cis-signaling' delivery of cytokines to tumor-reactive or pathogenic T cells. The lead immunology asset, ANV200, is a precision-engineered PD-1-depleting antibody in preclinical development for autoimmune and inflammatory diseases, with clinical testing planned in the near future. The legacy oncology portfolio comprises ANV600 (sunekafusp alpha), a first-in-class PD-1-targeted IL-2R-βγ agonist currently in Phase 1 with clinical benefit data presented at ASCO 2026 (42% disease control as monotherapy, 59% with pembrolizumab, including a CR in a CPI-resistant NSCLC patient); ANV700, a preclinical PD-1-targeted IL-21 fusion protein; and ANV419, an earlier-generation IL-2 fusion from prior clinical work.

Anaveon is pre-revenue and operates an enterprise partnering model. The company is actively seeking global development and commercialization partners for its oncology portfolio (ANV600, ANV700) via license, co-development, or acquisition structures, while advancing its core immunology pipeline internally toward clinical development. To date, Anaveon has raised approximately CHF 110 million in a December 2021 Series B led by Forbion with participation from Syncona, Novartis Venture Fund, Cowen Healthcare Investments, Pfizer Ventures, and Pontifax. Investors also include Blue Owl. The company has 11–50 employees and in 2026 underwent a comprehensive leadership overhaul — appointing Thaminda Ramanayake (CEO), Eric Zanelli (CSO), Jill Jene (CBO), and Thomas P. Mathers (Chairman) — alongside a strategic pivot emphasizing immunology over pure oncology.

Anaveon firmographics

Firmographics
Name
Anaveon
Legal name
Anaveon AG
Website
https://anaveon.com
Company type
Private
Founded year
2018
Operating status
Operating
Headcount range
11–50 employees
Short description
Anaveon AG is a Swiss preclinical-stage biotechnology company developing engineered antibodies and cytokine-based fusion proteins that selectively eliminate or reprogram pathogenic immune cells for autoimmune and oncology indications. It seeks global pharmaceutical partners for its oncology portfolio while advancing lead immunology asset ANV200 toward the clinic.
Ownership category
akta.pro rank

Anaveon industry classification

Industry
Product category
Biopharmaceuticals
NAICS
Pharmaceutical Preparation Manufacturing (325412)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAAABAF
Dendritic Cell & Other APC-based Therapies
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
SECONDARYHLAAAAAJ
Engineered Protein Therapeutics (de novo/AI-designed proteins, novel scaffolds)
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
SECONDARYHLAAAAAA
Monoclonal Antibody Therapeutics (mAbs)
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
SECONDARYHLAAAEAD
Vaccine Technology Platforms (mRNA, viral vector, protein subunit, inactivated/live-attenuated, VLP, DNA)
Healthcare & Life Sciences/Biotechnology & Biologics/Vaccines & Immunization Biologics
SECONDARYHLAAANAK
Personalized Therapeutic Design (neoantigen vaccines, individualized cell/gene therapies)
SECONDARYHLAAAEAH
Immunoglobulins & Passive Immunization Biologics (IVIG, hyperimmune globulins, antitoxins)
Healthcare & Life Sciences/Biotechnology & Biologics/Vaccines & Immunization Biologics

Keywords

  • Engineered antibodies
  • Cytokine therapeutics
  • Immuno-oncology biologics
  • Autoimmune disease therapies
  • Precision biologics

Where Anaveon is headquartered

Location

Headquarters

HQ city
Basel
HQ country
Switzerland
HQ region
Europe

Offices1 record

Markets served

Anaveon business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales

Revenue model

  1. Pipeline Development and Licensing: Pre-revenue preclinical biotech company. Primary value creation through advancing proprietary immunology pipeline (ANV200, ANV600, ANV700) toward clinical milestones, with intent to partner or out-license oncology assets. Revenue model will depend on eventual clinical and commercial partnerships, licensing deals, or co-development arrangements.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

Anaveon product offering

Product offering

Core offering

Anaveon develops precision-engineered antibodies and cytokine-based fusion proteins that act on upstream regulatory nodes of the immune system to selectively eliminate or reprogram pathogenic immune cells. Its lead immunology asset, ANV200, is a precision-engineered antibody designed for deep depletion of PD-1-expressing pathogenic T cells in autoimmune diseases, while its legacy oncology portfolio (ANV600, ANV700, ANV419) is being advanced through clinical and preclinical development and is open to global pharmaceutical partnering, licensing, co-development, or acquisition.

Product overview

Anaveon is developing a portfolio of engineered antibodies and cytokine-based therapies designed to selectively eliminate or reprogram pathogenic immune cells. The core pipeline includes ANV200 (preclinical, lead immunology asset for autoimmune diseases), while the legacy oncology portfolio includes ANV600 (Phase 1 IL-2R-βγ agonist), ANV700 (preclinical IL-21 fusion), and ANV419 (earlier generation IL-2 fusion). The company is seeking partners for its oncology assets while prioritizing its immunology pipeline.

Differentiator

Problem solved

Functional benefit

Products and services

  • ANV200 ANV200 is a precision-engineered antibody designed for deep depletion of the full spectrum of PD-1-expressing pathogenic T cells that drive harmful immune responses in autoimmune diseases. It acts on a key upstream control point of the immune system to reset pathogenic immune responses and restore tissue homeostasis, and is intended to influence multiple downstream disease mechanisms. The asset is currently in preclinical development, with clinical testing planned in the near future. It is being advanced as Anaveon's lead immunology asset.
  • ANV600 (sunekafusp alpha) ANV600 (sunekafusp alpha) is a first-in-class, non-blocking PD-1-targeted IL-2R-βγ agonist designed to selectively expand tumor-reactive PD-1+ CD8+ effector T cells while reducing toxicities historically associated with IL-2 therapy. It binds PD-1 on a unique non-blocking epitope distinct from checkpoint inhibitors and aims to activate tumor antigen-experienced T cells within the tumor microenvironment, with potential in checkpoint-refractory tumors and in combination with checkpoint inhibitors. The asset is in Phase 1 clinical development (EXPAND-1) and is part of the legacy oncology portfolio Anaveon is actively seeking to partner.
  • ANV419 ANV419 is an earlier-generation IL-2/anti-IL-2 fusion protein (not PD-1-targeted) with demonstrated safety in prior clinical studies. It is positioned as part of Anaveon's legacy oncology portfolio alongside ANV600 and ANV700, and is included in the oncology assets the company is actively seeking to partner, license, co-develop, or divest.

Quantifiable outcome

  • Disease control (CR, PR, or SD) observed in 42% of patients treated with ANV600 monotherapy and 59% of patients receiving ANV600 plus pembrolizumab
  • +5 more outcomes

Companies that use Anaveon

Customer profile

Named customers1 record

Segments1 record

Ideal customer profiles2 records

Anaveon technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature6 records

Anaveon partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • BioNTechminorStrategic or Co-development PartnerThaminda Ramanayake, now CEO of Anaveon, played a key role in CureVac's transformation and its acquisition by BioNTech in 2025. This represents a historical personal connection rather than a direct company-to-company partnership.

Scale indicators3 records

Recent moves5 records

Expansion highlights5 records

Anaveon competitors and assessment

Company assessment

Direct peers

  • Medicenna Therapeutics: Clinical-stage immuno-oncology company developing engineered IL-2/IL-4 Superkines and PD-1-IL-2 fusion proteins (MDNA11) — directly comparable mechanism and indication overlap with Anaveon's ANV600 and proximity-activated cytokine strategy.
  • Werewolf Therapeutics: Clinical-stage biotech using its PREDATOR/INDUKINE platforms to engineer tumor-selective, conditionally activated cytokine therapeutics — directly parallel to Anaveon's PD-1-targeted cytokine engineering approach.
  • NeoImmuneTech / Genexine: Developer of long-acting IL-7 (NT-I7/efineptakin alfa) and other cytokine-based immunotherapies — comparable cytokine engineering focus with overlapping oncology and immunology applications.
  • Bicycle Therapeutics: Clinical-stage biotech developing bicyclic peptide-based precision oncology therapeutics including immune cell engagers — comparable engineered biologic platform philosophy targeting tumor-selective immune activation.
  • Adagene: Clinical-stage biotech using AI-driven antibody engineering to develop precision immuno-oncology biologics, including PD-1-targeting candidates — comparable precision biologic approach with similar tumor-selective antibody engineering philosophy.
  • Cullinan Oncology: Multi-asset clinical-stage oncology company developing precision immunotherapies with similar partnered-program development model and platform-extension mindset.

Emerging players

  • Hookipa Pharma: Clinical-stage biotech developing arenavirus-based immunotherapies to induce potent T cell responses against oncology targets — overlapping immunotherapy focus with comparable precision immune-activation approach.
  • Compugen: Clinical-stage computational immunology company developing antibody-based therapeutics for cancer immunotherapy — comparable precision biologics development with computational discovery angle.

Broad incumbents

  • Eli Lilly: Major pharmaceutical company with a leading immunology/autoimmune franchise (Taltz, Olumiant) and active acquirer in the space — relevant as a potential strategic acquirer/partner and as the incumbent benchmark in autoimmune precision biologics.
  • Sanofi: Major pharmaceutical company with significant autoimmune and immunology franchise (Dupixent) and a venture arm that has historically backed cytokine engineering platforms — relevant both as a potential acquirer and as an incumbent benchmark.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks5 records

Key highlights6 records

Customer concentration

Anaveon social profiles

Digital presence

Anaveon financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Anaveon leadership team

Management profile

Number of profiles

Profiles4 records

Anaveon funding detail

Funding detail

Funding overview

Funding rounds2 records

Investors6 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Anaveon M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Anaveon

What does Anaveon do?

Anaveon develops precision-engineered antibodies and cytokine-based fusion proteins that act on upstream regulatory nodes of the immune system to selectively eliminate or reprogram pathogenic immune cells. Its lead immunology asset, ANV200, is a precision-engineered antibody designed for deep depletion of PD-1-expressing pathogenic T cells in autoimmune diseases, while its legacy oncology portfolio (ANV600, ANV700, ANV419) is being advanced through clinical and preclinical development and is open to global pharmaceutical partnering, licensing, co-development, or acquisition.

Is Anaveon a public or private company?

Anaveon is a private company. It is classified as venture growth investor backed and is currently operating.

When was Anaveon founded?

Anaveon was founded in 2018. It employs 11 to 50 people.

Where is Anaveon based?

Anaveon is headquartered in Basel, Switzerland, in the Europe region.

How does Anaveon make money?

One revenue line is on record: pipeline Development and Licensing.

Who are Anaveon's main competitors?

Direct peers on record are Medicenna Therapeutics, Werewolf Therapeutics, NeoImmuneTech / Genexine, Bicycle Therapeutics, Adagene and Cullinan Oncology. Emerging players are Hookipa Pharma and Compugen. Broad incumbents are Eli Lilly and Sanofi.

Does Anaveon have an API?

No public API is recorded for Anaveon.

What industry is Anaveon in?

Anaveon's product category is Biopharmaceuticals. Its primary akta.pro industry code is HLAAABAF, Dendritic Cell & Other APC-based Therapies, with a secondary code of HLAAAAAJ, Engineered Protein Therapeutics (de novo/AI-designed proteins, novel scaffolds). Its NAICS code is 325412 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
startupticker.chDeep-tech and biotech startups strengthen their leadership teamsFour Swiss deep-tech and biotech startups—Neural Concept, Corintis, Anaveon, and DEC Energy—have strengthened their leadership teams through executive appointments and committee formations as they enter their next growth phases. Neural Concept, which recently closed a USD 100 million Series C led by Goldman Sachs Alternatives, appointed Brett Chouinard as Board Chairman along with two additional executives, while Corintis hired Mindy Pyneeandee as CFO from HP and Anaveon promoted Laetitia Pouzol to Chief Scientific Officer. DEC Energy, a USI-incubated startup offering a B2B platform for renting photovoltaic assets and renewable energy certificates, established a Strategic & Operative Committee to guide its expansion.The Pharma LetterAnaveon promotes Laetitia Pouzol to role of CSOSwiss privately-held late-stage biotechnology company Anaveon has appointed Laetitia Pouzol as chief scientific officer, effective immediately. Pouzol previously joined the company in March 2025 as head of immunology and has been instrumental in advancing Anaveon's immunology programs.FinancialContent Business PageAnaveon Appoints Laetitia Pouzol as Chief Scientific OfficerAnaveon AG, a Swiss biotechnology company developing precision biologics for autoimmune and inflammatory diseases, has appointed Laetitia Pouzol as Chief Scientific Officer, succeeding Eric Zanelli who served as interim CSO during a period of organizational transition. Pouzol joined the company in March 2025 as Head of Immunology, where she advanced ANV200, the company's PD-1 depleting antibody, from early discovery through IND-enabling studies. The appointment positions her to lead Anaveon's scientific strategy as its lead immunology program advances toward clinical testing.GlobeNewswireAnaveon Appoints Laetitia Pouzol as Chief Scientific OfficerAnaveon, a late-stage biotechnology company based in Basel, Switzerland, announced the appointment of Laetitia Pouzol as Chief Scientific Officer. Pouzol was promoted internally from her role as Head of Immunology, where she had been advancing the company's lead program ANV200 since joining in March 2025. Eric Zanelli had served as interim CSO during the transition period.BioSpaceAnaveon Reports Clinical Benefit of ANV600 in the EXPAND-1 Phase 1 Clinical Trial at ASCO 2026 and Actively Seeks Partners for its Legacy Oncology PortfolioAnaveon presented new clinical data from its ANV600 oncology asset at ASCO 2026, showing antitumor activity in advanced solid tumors. The Phase 1 study reported a complete response in a CPI-resistant NSCLC patient and disease control in 42% of monotherapy patients. The company is seeking partners for its legacy oncology portfolio.startupticker.chSwiss biotechs progress across cardiology, oncology and allergy clinical programsFour biotechs reported clinical progress: HAYA Therapeutics dosed the first cohort in a Phase 1 cardiac fibrosis trial, Mabylon reported positive Phase 1a safety for its peanut allergy candidate, Molecular Partners published Phase 1 oncology data, and Anaveon sought partners after pivoting to immunology. Anaveon's ANV600 showed early signs of activity in a Phase 1 study.GlobeNewswireAnaveon Strengthens Leadership Team with Appointments of Eric Zanelli as Chief Scientific Officer and Jill Jene as Chief Business OfficerAnaveon AG, a late-stage preclinical biotechnology company headquartered in Basel, Switzerland, announced the appointments of Eric Zanelli as Chief Scientific Officer and Jill Jene as Chief Business Officer. Both executives bring extensive track records in immunology, biotech business development, and corporate strategy, with Jill Jene having led over $6 billion in transactions and Eric Zanelli having raised more than $200 million in venture capital. The company stated these hires are intended to accelerate its transition into clinical development and advance its lead asset ANV200, a precision biologic for autoimmune diseases.BioSpaceAnaveon Strengthens Leadership Team with Appointments of Eric Zanelli as Chief Scientific Officer and Jill Jene as Chief Business OfficerAnaveon appointed Eric Zanelli as Chief Scientific Officer and Jill Jene as Chief Business Officer. The appointments aim to accelerate clinical advancement and pipeline expansion for its precision biologics targeting autoimmune and inflammatory diseases.BioSpaceAnaveon Appoints Thomas P. Mathers as Chair of the Board of DirectorsAnaveon appointed Thomas P. Mathers as Chair of its Board of Directors, with the appointment to be confirmed at the June Annual General Meeting. Dieter Weinand, who served as Chair since 2024, stepped down. Mathers brings over 32 years of life sciences leadership, including roles at Aer Therapeutics and CoLucid Pharmaceuticals.GlobeNewswireAnaveon Announces Presentation of Positive ANV600 Clinical Data at ASCO 2026 and Actively Seeks Partners for its Legacy Oncology PortfolioAnaveon will present ANV600 clinical data from the EXPAND-1 Phase 1 study at ASCO 2026, showing manageable safety and tumor shrinkage. The company is seeking partners for its oncology portfolio, including ANV700, while prioritizing its immunology pipeline.